Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. ROIV
2. HUVR:IN
3. LAD
4. ASML
5. NVS
6. TTE
7. ANET
8. NKE
9. BE
10. PANW

Go back to Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
(NASDAQ: IONS) Delayed: 58.09 --0 (-0%)
Previous Close $58.09    52 Week High $62.68 
Open $58.09    52 Week Low $19.59 
Day High $58.09    P/E N/A 
Day Low $58.09    EPS $0.00 
Volume 122,043